BioCentury
ARTICLE | Top Story

Array gains on Phase II asthma data

July 24, 2013 12:52 AM UTC

Shares of Array BioPharma Inc. (NASDAQ:ARRY) jumped on Tuesday after the biotech reported that twice-daily oral ARRY-502 for four weeks met the primary endpoint in a 184-patient Phase II trial to treat persistent allergic asthma. ARRY-502 improved pre-bronchodilator forced expiratory volume in 1 second (FEV1) from baseline to day 29 vs. placebo (placebo-adjusted improvement of 3.9%, p=0.02). In a pre-defined subset of patients based on the median baseline value of an undisclosed T helper type 2 (Th2)-associated biomarker, ARRY-502 led to a placebo-adjusted improvement in pre-bronchodilator FEV1 from baseline to day 29 of 6.8% (p=0.008). Array declined to provide details on the subset. ...